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Abstract The primary prevention of cardiovascular dis-
ease is a public health priority. To assess the costs and
benefits of a Polypill Prevention Programme using a daily
4-component polypill from age 50 in the UK, we deter-
mined the life years gained without a first myocardial
infarction (MI) or stroke, together with the total service
cost (or saving) and the net cost (or saving) per year of life
gained without a first MI or stroke. This was estimated on
the basis of a 50 % uptake and a previously published
83 % treatment adherence. The total years of life gained
without a first MI or stroke in a mature programme is
990,000 each year in the UK. If the cost of the Polypill
Prevention Programme were £1 per person per day, the
total cost would be £4.76 bn and, given the savings (at
2014 prices) of £2.65 bn arising from the disease pre-
vented, there would be a net cost of £2.11 bn representing a
net cost per year of life gained without a first MI or stroke
of £2120. The results are robust to sensitivity analyses. A
national Polypill Prevention Programme would have a
substantial effect in preventing MIs and strokes and be
cost-effective.
Keywords Cost–benefit analysis  Polypill  Primary
prevention  Cardiovascular diseases  Stroke  Myocardial
infarction
Introduction
Cardiovascular disease, particularly myocardial infarction
(MI) and stroke, is one of the leading causes of death and
disability throughout the world. This is so even in countries
such as theUSAandUnitedKingdom (UK)where age specific
mortality rates from MI and stroke have declined [1, 2].
It is recognised that the primary prevention of cardio-
vascular disease is important. To this end, recommenda-
tions that people should reduce their salt, sugar and
saturated fat intake, take regular exercise, control their
weight, and avoid smoking, are widely accepted. In addi-
tion it is generally accepted that people at sufficiently high
risk of an MI or stroke should be identified so that they can
receive preventive medication. This medication could be in
the form of a combination pill (polypill) consisting of a
statin to lower LDL cholesterol, and low dose blood
pressure lowering drugs to reduce blood pressure [3–6]. It
has been established, on the basis of epidemiological evi-
dence and from randomised trials, that reducing these risk
factors has a substantial impact in reducing the risk of MIs
and strokes [6, 7].
The results presented in a previous paper [8, 9] are
intended to guide individuals considering participation in a
Polypill Prevention Programme by showing that one in
three people who take the polypill will benefit and gain, on
average, 8 years of life without a first MI or stroke. The
present paper is intended to produce results to guide poli-
cymakers considering setting up a Polypill Prevention
Programme as a public service. We assess the economic
implications of the polypill approach with particular ref-
erence to its possible adoption by the UK National Health
Service. The results may be relevant to other similar health
services throughout the world. Our aim was to determine
(i) the total number of years of life gained without a first
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MI or stroke (years in a group offered the polypill minus
years in an identical group not offered the polypill), (ii) the
total annual cost, and (iii) the cost (or saving) per year of
life gained in this way from a Polypill Prevention Pro-
gramme for individuals aged 50 and over in the UK.
Methods
We performed a standard life table analysis based on meth-
ods and results published in Wald and Morris [8, 9] to
determine the number ofMIs and strokes and the years of life
gained without a first MI or stroke from delivering a public
health prevention programme based on a four component
polypill consisting of 20 mg simvastatin, 2.5 mg amlodip-
ine, 25 mg losartan and 12.5 mg hydrochlorothiazide
(recognising that, in the future, alternative formulations may
be advantageous). Briefly, life tables startedwith the 453,913
males and 465,472 females aged 50 in theUK in 2013 [10] by
applying annual age- and sex-specific risks of a first MI, first
stroke and death from causes other than MI and stroke sep-
arately to create two cohorts of people aged 50 in the UK in
2013: one cohort taking the polypill and the other not taking
the polypill. At the end of each year of age a person could be:
(i) alive without ever having had anMI or stroke, or (ii) alive
or dead having had anMI or stroke, or (iii) dead without ever
having had anMI or stroke. Over time, individuals can move
from 1 to 2 or from 1 to 3, but not from 2 to 3, 2 to 1, or 3 to 1.
For people who did not take the polypill, the probability of
moving from state 1 to 2 was the age-sex specific annual
incidence of the first occurrence of an MI or stroke, and the
probability of moving from state 1 to 3 was the age-sex
specific annual mortality from all causes, excluding MI or
stroke. For people taking the polypill, the probability of
moving from state 1 to 2 was the age-sex specific annual
incidence of the first occurrence of anMI or strokemultiplied
by the age-sex specific relative risk reductions from taking
the polypill, and the probability of moving from state 1 to 3
was the same as for people who did not take the polypill (see
‘‘Appendix’’ for the derivation of the probabilities used). The
survival times and number of first MIs and strokes were
accumulated. The costs were obtained by multiplying the
survival times by the costs of taking the polypill daily and the
total costs of first MIs by the number of first MIs multiplied
by the average cost of treating anMI and the total costs of first
strokes by the number of first strokes multiplied by the
average cost of treating a stroke. The average cost of treating
an MI was taken from Luengo-Fernandez et al. [11] and the
average cost of treating a stroke was taken from Saka et al.
[12]. The costs of treating an MI and stroke were adjusted to
the cost in 2014 using the UK Treasury inflation figures [13].
Details of how the costs from these papers were taken are
given in the ‘‘Appendix’’.
The non-discounted lifetime cost, saving on treatment and
years of life gained without a first MI or stroke from imple-
menting a Polypill Prevention Programme in a cohort of
people aged 50 were estimated. If the size of each annual
cohort of people aged 50 is constant over time, these esti-
mates are equivalent to annual figures for a mature pro-
gramme. The programme becomes mature after about
20 years when there is a balance in the number of people in
two groups: (i) the annual number who have an MI or stroke
prevented and (ii) the annual number who die (from any
cause) or have a non-fatal MI or stroke among everyone who
had an MI or stroke prevented at any time in the past. Then
the programme is in a steady state in which it is necessary to
compare only the constant annual cost of the programme
with the constant annual monetary value of the benefit.
Our estimates of the preventive effects of the polypill relate
only to the incidence of MI and stroke. The estimate of 17 %
for non-adherence was taken from experience of a Polypill
Prevention Programme using the separate polypill drug
components [14]. Non-adherent individuals were modelled to
participate in a Polypill Prevention Programme for 1 month,
without experiencing any health benefits, before dropping out
of the programme and not involving any further cost.
The prescription, dispensing, distribution and manufac-
turing of the polypill was considered at several cost levels per
(daily) pill, ranging from £0.50 to £1.50. A private Polypill
Prevention Programme is already available online (polyp-
ill.com) at a cost per polypill of £1.05, which includes the
complete cost of delivering the service. We separately allo-
cated a £5 one-off cost per person invited to join the pro-
gramme, to cover invitation and programme start-up
expenses. A summary of these unit costs is set out in Table 1.
The annual years of life gained without a first MI or
stroke arising from a Polypill Prevention Programme was
estimated, as well as: (i) annual health service saving arising
from the reduction in MI or stroke events; (ii) annual health
service cost of the Polypill Prevention Programme; (iii) net
annual health service cost (or saving) arising from (i) and
(ii); and (iv) net cost (or saving) per MI or stroke prevented.
These estimations were performed for different costs of
providing a daily polypill. A hypothetical ‘‘best case’’ situ-
ation with 100 % uptake and 100 % adherence and a
‘‘working case’’ situation with 50 % uptake of the polypill
and 83 % adherence were considered.
We also carried out sensitivity analyses by varying the
key input variables in turn by ±25 %.
Results
Table 2 shows the total annual years of life gained without
a first MI or stroke in the UK in a hypothetical best case in
which the polypill uptake and adherence rates are both
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100 % and in a more realistic working case with a 50 %
uptake and 83 % adherence (2,390,000 and 990,000 years
respectively). The table also shows the extra cost or saving
(i.e. net cost or saving) per year of life gained without a
first MI or stroke according to the daily per person cost of
the Polypill Prevention Programme. For example, the net
cost per year of life gained without a first MI or stroke
would be £2120 if the daily cost of a Polypill Prevention
Programme was £1 per person.
Table 3 shows the total annual health service savings
made through preventing MI and strokes in a Polypill
Prevention Programme (£6.39 and £2.65 bn for the best
case and working cases respectively). The table also shows,
according to the specified daily per person cost of the
programme, the total annual UK cost, and the net annual
UK cost. For example, if the daily cost of the programme
were £1 per person, the total annual cost in the working
case would be £4.76 bn and the net annual cost would be
£2.11 bn (£4.76–£2.65 bn). The cost estimates for each of
the four countries in the UK are shown in the ‘‘Appendix’’
based on their populations [10]. The total years of life
gained without a first MI or stroke are 828,000, 89,000,
47,000 and 28,000 respectively for England, Scotland,
Wales and Northern Ireland.
Table 3 also shows that if the cost of providing the
polypill were relatively low (£0.50 per person per day)
there would be a net saving per year of life gained without
a first MI or stroke. As the cost increases, the net saving per
year of life gained gradually disappears and turns into a net
cost. For example, if the cost per person per day were £1.50
the net cost per year of life gained without a first MI or
stroke would be £4520 (Table 2). If the cost per person per
day were £0.56, a Polypill Prevention Programme would be
cost neutral.
Tables 4 and 5 show the effect on the working case of
altering in turn four key input estimates (incidence of MI
and stroke, polypill efficacy, NHS cost per MI and stroke,
and non-adherence) by setting these input estimates at
25 % less than those used in the model and at 25 % more,
thus providing an indication of how such variation influ-
ences the results (i.e. a sensitivity analysis). This sensitivity
analysis shows that none of the alterations affects the cost
per year of life gained without a first MI or stroke by more
than about ±£1000.
Table 1 Input estimates used in the analysis
Item Value
Program invitation per person invited (one-off invitation letter and infrastructure cost) £5
Cost of providing polypill (per person per day)c £0.50, 0.75, 1.00, 1.25 and 1.50
Average healthcare cost of an MI (per clinical event)c £29,900 [11, 15]
Average healthcare cost of a stroke (per clinical event)c £50,500 [12]
Polypill uptake 50 %
Polypill adherence 83 % [14]
Polypill LDL cholesterol reductiona 1.54 mmol/L [5]
Polypill diastolic BP reductiona 10.7 mmHg [6]
Age-specific relative risk for MI on polypill at age 60b 0.23 [5, 16]
Age-specific relative risk for stroke on polypill at age 60b 0.28 [5, 6, 16]
a Simvastatin 20 mg, amlodipine 2.5 mg, hydrochlorothiazide 12.5 mg, losartan 25 mg
b Age-specific relative risks from age 50 were applied in the model
c At 2014 prices
Table 2 Total years of life gained and net costs (at 2014 prices) per year of life gained without a first myocardial infarction (MI) or stroke in
people aged 50 and over in a UK Polypill Prevention Programme
Total years of life gained
without a first MI or stroke in
the UK (thousand)
Daily cost of Polypill Prevention Programme per person (£)
0.50 0.75 1.00 1.25 1.50
Net cost or saving (–) per year of life gained without a first MI or stroke
(£) (£) (£) (£) (£)
Best case
(100 % uptake, 100 % adherence) 2390 2280 920 2120 3310 4510
Working case
(50 % uptake, 83 % adherence) 990 2270 920 2120 3320 4520
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Figure 1 shows the impact of polypill uptake on pro-
gramme net cost and overall years of life gained without a
first MI or stroke. Both increase with increasing uptake
such that the cost per year of life gained without a first MI
or stroke remains almost constant.
Discussion
Our analysis shows that a Polypill Prevention Programme
in which people aged 50 and over are offered a daily
polypill would be effective in the prevention of MI and
stroke. In our working case approximately one million
years of life without a first MI or stroke in the UK would be
gained every year. There are few public health programmes
that could deliver such great gains in reducing morbidity
and mortality in many countries throughout the world.
The cost of a mature Polypill Prevention Programme per
year of life gained without a first MI or stroke would be
approximately £2000 if the cost of providing the polypill
were £1 per day per person and, in the working case, £2
billion annually for the UK as a whole (approximately
1.5 % of UK Public Sector Health Expenditure in 2014
[17]). Our analysis uses the concept of ‘‘years of life gained
without a first MI or stroke’’ instead of simply ‘‘years of life
gained’’, because our focus is the prevention of non-fatal
and fatal events. In some instances years of life gained may
be the preferred measure of health benefit. An example is
breast cancer screening where the method of prevention is
early cancer detection and its treatment, in which years of
life gained without being aware of breast cancer would be
reduced. However in the primary prevention of a disorder
that causes early death and morbidity, the preferred measure
is life years gained without the disorder. Also, we deliber-
ately did not adopt an adjusted measure known as ‘‘quality
adjusted life years’’ or ‘‘QALYs’’. Any adjustment due to
disability arising from anMI or stroke would not be relevant
in our analysis because we estimated years of life gained
without either of these events. In any event, if we had
estimated total life years gained, we would have been
reluctant to use any adjustments which imply that the life of
a disabled individual is of less value than that of a similar
individual living without disability. It is increasingly
recognised that the quality of life is a personal matter, and
not one where the State or other agencies should impose
their judgement [18, 19]. Notwithstanding these consider-
ations, a cost of £2000 per year of life gained without a first
MI or stroke is amply cost-effective in relation to the con-
ventionally accepted maximum cost figure of between
£20,000 and £30,000 per quality adjusted year of life gained
allowed by NICE [20].
Our analysis combines data on males and females. The
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year of life gained without an MI or stroke is about £1000
more in females thanmales if the cost of delivering a polypill
service is £1 per person per day. If the costs were set to be the
same in both sexes the female cut-off would be about
10 years later (age 60) but, on average, women would lose
about 8 months of extra lifewithout anMI or stroke. The sex-
specific policy trade-offs are finely balanced and do not
justify separate age cut-offs for males and females [21].
The sensitivity analyses indicate that our estimates are
robust to variations in the factors considered (Tables 4 and
5). For example, it is likely that a Polypill Prevention
Programme will be taken up more readily among people in
higher socio-economic groups. This will have only a
modest effect on our estimates; even if the MI and stroke
incidence were three times as great in lower socio-eco-
nomic groups than in higher, and if twice as many people
in higher socio-economic groups were to take up the
polypill, the incidence of these disorders would be about
10 % lower in people taking the polypill than in the pop-
ulation as a whole, well within the limits of our sensitivity
analysis on incidence.
Our results are not influenced by secondary prevention
services because our paper is limited to the prevention of
first events. The estimates are based on introducing a
Polypill Prevention Programme in a population not
receiving medication for primary prevention. At present in
England there is a primary prevention programme provided
by the National Health Service called ‘‘Health Checks’’
that involves adopting a Framingham-type screening
approach. Although it might be argued that the polypill
approach should be directly compared with this approach,
there is both a scientific and a practical reason not to do so.
The scientific reason is that provided the cost of a Polypill
Prevention Programme is not excessive, it would be more
cost effective, as shown in an earlier analysis comparing
age screening with screening using multi-factor risk scores
[22]. The practical reason is that the English Health Check
programme lacks specificity and clarity over the interven-
tions offered, and over the effect of these interventions in
reducing morbidity and mortality, thereby making it
impossible reliably to assess costs and benefits. The
Polypill Programme overcomes these weaknesses and
should be assessed independently of any other intervention.
The effect of a Polypill Prevention Programme on the
total years of life gained without a first MI or stroke in the
UK will depend on the size of the progressive annual
cohorts of people aged 50, which can vary by up to 15 %
from year to year. As a result, the total of such years gained
is unlikely to fall below 850,000. This variation in the
50-year-olds cohort size does not, however, affect the cost
per year gained, because as less people take up the polypill,
the benefits and costs decline together almost pro rata.
The years of life gained without a first MI or stroke
decline with increasing age of starting. For example,
starting at age 55 instead of 50 in the working model, the
gain in years of life without a first MI or stroke is reduced
by about 10 % (910,000 instead of 990,000). At the same
time, the net cost is reduced by about 30 % (£1.50 bn
instead of £2.11 bn) and the cost per year of life gained
without a first MI or stroke is reduced by about 20 %
(£1650 instead of £2120). The disadvantage in setting a
higher age cut-off, of course, is the failure to prevent MIs
and strokes in younger people, and a reduction in overall
public health benefit.







Daily cost of Polypill Prevention Programme per person (£)
0.50 0.75 1.00 1.25 1.50
Net cost or saving per year of life gained without a first MI or stroke
(£) (£) (£) (£) (£)
Incidence of MI and stroke
25 % less 790 240 1760 3290 4820 6350
25 % more 1180 (530) 460 1460 2460 3460
Polypill effectiveness
25 % less 800 330 1790 3260 4730 6190
25 % more 1150 (640) 400 1440 2490 3530
Cost of MI and stroke
25 % less 990 390 1590 2790 3990 5190
25 % more 990 (940) 250 1450 2650 3850
Non-adherence to treatment
25 % less 1040 (280) 920 2120 3320 4520
25 % more 940 (270) 920 2120 3320 4520
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Reducing LDL cholesterol and blood pressure will
prevent cardiovascular diseases other than MI and stroke,
such as angina pectoris and aortic aneurysm. The Polypill
Prevention Programme may also have a beneficial effect
in preventing arteriosclerotic dementia. There is evidence
that use of the polypill will reduce the prevalence of
headaches by approximately one-third [23]. Most of the
side effects of the polypill relate to intolerance and are
not serious. This will result in some people deciding to
stop taking it (in our example 17 %). The main serious
side effect is rhabdomyolysis, arising from the use of
statins, with an estimated risk of approximately 3 per
100,000 persons per year, and mortality of approximately
0.3 per 100,000 persons per year [24]. This estimate is
consistent with the observation that in 2013 in England
and Wales 7.6 million people took statins [25, 26] and 86
deaths were recorded as being due to rhabdomyolysis
(ICD-10, M62.8) [27], of which about 20 would have
been statin related. Statins increase the incidence of dia-
betes by an estimated 9 % but it is good practice to
prescribe, in such cases, the components in the polypill,
as the benefit far outweighs the risks [28].
Discounting the value of future health benefits and
financial cost/saving in economic analyses of public health
programmes is debatable [18, 29, 30], but it is irrelevant to
our analysis. Once the programme is mature, there is a
steady state between annual costs and benefits, both being
constant from year to year, thus dispelling any possible
rationale for discounting.
A challenge in introducing an NHS Polypill Prevention
Programme will be to secure professional and public
acceptance that the focus should be on providing effective
and safe preventive treatment, rather than paying more
attention to screening measurements [22]. Such measure-
ments add little beyond the use of age to the prediction of
cardiovascular disease. They do, however, add significantly
to the workload of medical staff, arising from the associated
extra medical consultations, laboratory tests, implementa-
tion of screening algorithms and risk counselling. Many
doctors may feel that an individual should receive choles-
terol lowering treatment only if the LDL cholesterol is raised
or blood pressure lowering treatment only if his or her blood
pressure is raised above essentially arbitrary cut-off values.
This however means that some people at risk do not receive
preventive treatment and others receive only some of the
components in the polypill, when using all of them confers
greater efficacy. Preventive treatment should involve
reducing both LDL cholesterol and blood pressure, regard-
less of pre-treatment levels, because the benefit of doing so is
not limited to people with high levels [16, 31, 32].
If everyone aged 50 and over in the UK were invited to
join a Polypill Prevention Programme in 1 year, approxi-
mately 22 million people would be invited, representing
about 2300 per GP practice in year one, and about a hun-
dred in each year thereafter. If recruiting 2300 people in a
single year poses too heavy an administrative burden on
each practice (about 45 per week), recruitment could be
phased over 2 years. That would mean about 1200 invita-
tions per year in the first 2 years (about 22 per week) and
about 100 per year thereafter. Perhaps more importantly,
once a Polypill Prevention Programme were underway,
there would be only about 100 new invitations each year
per practice.
General Practice surgeries would identify people on their
list when they reach their 50th birthday, write to them to
determine contraindications to preventive cardiovascular
disease treatment (such as certain pre-existing diseases or
medications which each person would indicate in a response
to a short list of questions) and, if eligible, offer them a
polypill to diminish the likelihood of future MIs and strokes.
Acceptance could be done by mail or email and a prescrip-
tion sent to a pharmacy for dispensing. The polypill could be
sent to each polypill participant by post, or could be col-
lected from a designated local pharmacy. The process could
be implemented and monitored in a largely automated way,
releasing General Practitioner time and resources for
patients with medical problems.
Identifying people by age as being eligible for a polypill
avoids them feeling that they are patients or being regarded
as patients. They do not have a medical disorder that needs
treatment; they choose to take a preventive medication to
avoid becoming a patient. The UK National Health Service
(NHS) and other collectively funded health care systems
such as US Health Maintenance Organizations are ideal
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Fig. 1 Annual life years gained without a first myocardial infarction
or stroke and annual programme cost at 2014 prices for a Polypill
Prevention Programme for individuals aged 50 and over according to
uptake of polypill (£1 daily cost of providing a polypill, adherence to
treatment 83 %)
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Others who have conducted cost-effectiveness analyses,
adopting different screening strategies and different esti-
mates of cost, have concluded that cardiovascular disease
prevention with a polypill is cost-effective, across a range
of estimates of drug efficacy and treatment cost [33–35].
For example, an Australian study [35] ranked a polypill
strategy as one of the most cost-effective interventions in
the prevention of cardiovascular disease. Another study
assessed an age-based screening strategy in low and middle
income countries using an age cut-off of 55 years as being
cost-effective [34]. In 2014 the US Rand Corporation
conducted a case-study of ‘‘A Cardiovascular Polypill’’
[36] and again found it to be cost-effective [37].
Our analysis adds to the information available from pre-
vious economic analyses of the polypill. It focuses on three
important measures relevant to assessing the merits of a
National Polypill Prevention Programme: net cost for a total
programme, years of life gained without a first MI or stroke,
and net cost per year of life gained without a first MI or
stroke. These estimates are here applied to theUKas awhole,
to guide the National Health Service and other similarly
managed health care services to develop policy in this area.
The NHS could introduce a Polypill Prevention Programme
generally or conduct a prior demonstration project in a large
sample of GP practices within the UK, and audit the project.
From the perspective of each individual, and that of
society as a whole, a Polypill Prevention Programme offers
considerable health benefits at a relatively low cost.
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Appendix
Details of the data used in the life table analysis to deter-
mine the number of first myocardial infarctions (MIs) and
strokes and the years of life gained without a first MI or
stroke are given below:
1. The incidence of first myocardial infarction (MI) or
stroke in England and Wales in 2010 in people not
taking statins or blood pressure drugs.
2. The age specific relative risks of a stroke or myocardial
infarction (MI) whilst on the polypill.
3. The age-specific mortality from all causes other than
MIs or strokes in England and Wales 2010.
In order to be consistent with the earlier paper [8, 9], the
same 2010 incidence and mortality rates were used.
However, 2013 population figures were used, in order to
have the most up to date estimates of the costs and benefits
of a Polypill Prevention Programme.
The incidence of first myocardial infarction (MI)
or stroke in England and Wales in 2010 in people
not taking statins or blood pressure drugs
To estimate this, we first used published estimates of the
incidence of these disorders in 1985–1995 and then
adjusted them for the reductions in incidence that occurred
between 1995 and 2010, and then took account of the fact
that about 30 % of people aged 50 and older were taking
statins or blood pressure drugs in 2010.
Annual incidence of first MI and stroke from 1985
to 1995
The following unpublished weighted logistic regression
equations from the meta-analysis reported by Law et al. [38]
wereused to obtain yearly age specific incidence rates formen:
incidence of firstMI¼ exp 8:9041þ0:06148yearsð Þ=
1þ exp 8:9041þ0:06148yearsð Þð Þ; and
incidence of first stroke¼ exp 11:3454þ0:08769yearsð Þ=
1þ exp 11:3454þ0:08769yearsð Þð Þ:
For women:
incidence of firstMI¼ exp 12:5712þ0:10332yearsð Þ=
1þ exp 12:5712þ0:10332yearsð Þð Þ; and
incidence of first stroke¼ exp 11:8133þ0:09112yearsð Þ=
1þ exp 11:8133þ0:09112yearsð Þð Þ:
Allowing for the decrease in incidence and case
fatality from 1985–1995 and to 2010
The incidence estimates in the previous paragraph relate to
1985–1995. Since then mortality from MI and stroke has
decreased [ONS 1985–1995 [39] vs ONS 2010 [40, 41] as
shown in column 3 in Table 6], as a result of both a
decrease in incidence and a decrease in case-fatality. Two
studies [2, 42] reported the contributions to the decrease in
mortality arising from a decrease in incidence
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(I) compared with a decrease in case fatality (CF) (column
4 in Table 6). The decrease in incidence of first MI and
strokes from 1985–1995 to 2010 (column 5) was estimated
using the results of these two studies and assuming I and
CF changed, over time, by the same proportion (P) (so that
the decrease in incidence is P 9 I and the decrease in case
fatality is P 9 CF). Then the decrease in mortality is
1 - ((1 - P 9 I) (1 - P 9 CF)). For example in the
second row of Table 6 the decrease in mortality is 67 %,
so 0.67 = 1 - (1 - 0.30P)(1 - 0.43P) which can be
rearranged so that 0.129P2 - 0.73P ? 0.67 = 0. This
quadratic equation has two solutions; P = 1.15 and
P = 4.51. P = 4.51 leads to a decrease in incidence
greater than 100 %, which is not possible, so the decrease
in incidence, P 9 I = 1.15 9 30 % = 35 % (as given
in col 5).
The age specific incidence of first MI and stroke in 2010
was estimated by multiplying the estimated decreases in
incidence from 1985–1995 to 2010 (column 5 in Table 6)
by the logistic regression equations for the age specific
incidence of first MI and stroke in 1985–1995 given in
Annual incidence of first MI and stroke from 1985 to 1995.
Allowing for the current use of components
of the polypill in 2010
Around 30 % of people aged 50–99 were currently taking
blood pressure lowering drugs [43] or statins [44] in 2010.
Therefore the estimated age specific incidence in 2010 at each
age was adjusted by 1/(0.7 ? 0.3 9 age specific relative risk
as given in Table 7) to estimate the incidence in people not
taking statins or blood pressure drugs. Details of the estima-
tion of the age specific relative risks are given below.
Estimating the age specific relative risks of a stroke
or myocardial infarction (MI) on the polypill
Table 7 shows the age specific relative risk of a first MI or
stroke based on four sources [3, 5, 6, 16]. The age specific
relative risk estimates by single year of age for people aged
50–90 were obtained by linear interpolation using the rel-
ative risks in appendix Table 7. For people age 90 and
above the relative risks were assumed to be constant.
Estimating the age-sex-specific mortality
and deaths from all causes other than an MI
or stroke in England and Wales in 2010
Age-sex-specific mortality rates were obtained from the
ONS publication Mortality Statistics: Deaths Registered in
England and Wales (Series DR), 2010 [40]. The mortality
rates from causes other than MI and stroke were calculated
as the all-cause mortality rates minus the mortality rates
from MI or stroke. These age-sex specific rates were
applied to the number of people in the two 50 year old
Table 6 Estimated decrease in incidence of MI and stroke from 1985–1995 based on mortality changes and the contributions from changes in
incidence and case-fatality
Gender Disorder Observed decrease in mortality from
1985–1995 to 2010 (%)
Decrease in incidence;
Decrease in case fatality
[2, 42] (%)
Estimated decrease in incidence
from 1985–1995 to 2010 (%)
Female MI 76 31a;
29a
53
Female Stroke 67 30b;
43b
35
Male MI 69 33a;
24a
51





Table 7 Age specific relative risk estimates
Age taking
polypill
Relative risk of a first
stroke on polypilla







a Polypill contains simvastatin 20 mg, amlodipine 2.5 mg, losartan
25 mg, and hydrochlorothiazide 12.5 mg
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cohorts specified in the Methods (one taking the polypill
and one not) to estimate the number of deaths occurring
from causes other than MI or stroke each year. These were
subtracted from the number of people in each cohort who
were alive at the end of each year without having had an
MI or stroke to reduce the size of the cohorts as they aged.
Calculation of health service cost associated
with the treatment of myocardial infarction
The total NHS healthcare cost for coronary heart disease
used in this paper was £3460 million (2004 prices) [11].
This sum is taken from Table 2 in the reference cited [11]
by subtracting the private healthcare cost of £399 million
from total healthcare cost of £3859 million.
Coronary heart disease includes conditions related to
myocardial infarction such as angina. The vast majority of
coronary heart disease cost is myocardial infarction. Also,
in expectation, the polypill will reduce incidence of
coronary heart disease other than myocardial infarction
such as angina so it is reasonable to use overall coronary
heart disease cost in the calculation.
In 2006, there were an estimated 146,000 myocardial
infarctions in theUK [15]. Therefore, the estimated coronary
heart disease cost permyocardial infarction is £3460million/
146,000, or £23,699 (in 2004 prices). Taking into account
inflation [13], current cost in 2014 was £29,900.
Calculation of health service cost associated
with the treatment of stroke
The total NHS healthcare cost for stroke has been esti-
mated at £4384 million in 2005 (Table 2 in the reference
cited) [12].
The same reference gives an estimate of 106,675 strokes
a year (supplementary data of Saka et al. [12]). Therefore,
the estimated cost per stroke is £4384 million/106,675, or
£41,097 (in 2005 prices). Taking into account inflation
[13], current cost in 2014 was £50,500.
Table 8 Numbers of males and females aged 50 in 2013 in the UK
[10]





Northern Ireland 12,984 12,985
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Calculating the costs separately the four countries
in the UK
In order to calculate the total costs separately for each
country in the UK the cohort analysis was repeated with the
numbers of males and females aged 50 in 2013 in each
country used instead of the number of males and females
aged 50 in the UK (see Tables 8, 9).
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